FOLR2 and neoplasm: Perhaps, manipulating the preinjected folic acid doses to reduce liver uptake while minimally affecting tumor uptake may be possible; or, an inhibitor selectively targeting activated FR-β macrophages instead of FR-α tumor may be an option in the future.